Multiple Myeloma Trial Landscape (October 2026)

Last updated: Oct 4, 2026 · Built by a patient who got tired of scrolling ClinicalTrials.gov

Overview

Active interventional trials with status RECRUITING or NOT_YET_RECRUITING. A multi-phase trial (e.g. 1/2) is counted in each of its phases.

Mechanism Breakdown

Recruiting trials grouped by drug class. Trials with unclassifiable or non-therapeutic interventions are excluded from this view.

Recently Updated Trials

NCT	Phase	Title	Mechanism
NCT06904066	1	Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies	Patient-specific neoantigen TCRs -- autologous T cell receptor (TCR) transduced T cells
NCT07053436	2	Horizon Two: HR NDMM (MMRC-100)	Bispecific monoclonal antibodies targeting multiple myeloma antigens + stem cell transplant -- antibody therapy and transplantation
NCT07732712	2, 3	Isa-VRdlite for of Frail and/or Much Older Patients With High Risk Newly Diagnosed Multiple Myeloma Base on Circulating Plasma Cells	CD38 -- monoclonal antibody
NCT04414475	2	A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM.	XPO1 -- nuclear export inhibitor (Selinexor)
NCT07376733	—	Effects of Controlled Breathing on Cardiorespiratory Variables in Multiple Myeloma	Unknown mechanism

Top Sponsors

Sponsor	Recruiting trials
Institute of Hematology & Blood Diseases Hospital, China	29
Regeneron Pharmaceuticals	11
Memorial Sloan Kettering Cancer Center	11
Janssen Research & Development, LLC	11
Xuzhou Medical University	9

Geographic Distribution

Countries/regions with the most active trial sites for multiple myeloma. A multi-site trial is counted once per country/region.

Emerging Classes

Phase-1 trials whose listed start date falls within the last 12 months — the leading edge of the field.

Start	NCT	Title	Mechanism
Jun 30, 2027	NCT06435910	Engineered Dendritic Cell Vaccines for Multiple Myeloma	Tumor antigens -- dendritic cell vaccine
Jun 30, 2027	NCT06006741	Universal CAR-T Cells Targeting Multiple Myeloma	Multiple myeloma antigens -- universal chimeric antigen receptor T cell therapy (CAR-T)
Apr 12, 2027	NCT07463807	Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment	BCMA + CD3 -- bispecific antibody (teclistamab); Cereblon modulator (pomalidomide); Proteasome inhibitor (carfilzomib)
Dec 31, 2026	NCT06429150	Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma	Multiple myeloma antigens -- CAR-T cell therapy
Dec 31, 2026	NCT03271632	Multi-CAR T Cell Therapy in the Treatment of Multiple Myeloma	Multiple cancer cell surface antigens -- chimeric antigen receptor (CAR) T cell therapy
Dec 1, 2026	NCT07600151	Etenta-Isa-VRd in Newly Diagnosed High-Risk Multiple Myeloma	CD38 -- monoclonal antibody (isatuximab); Proteasome -- proteasome inhibitor (bortezomib); Cereblon -- immunomodulatory agent (lenalidomide); Glucocorticoid receptor -- corticosteroid (dexamethasone); Unknown mechanism (etentamig)
Dec 2026	NCT07831122	Study of Belantamab Mafodotin, Cevostamab, Pomalidomide for RRMM Patients (MAPLE)	BCMA + CD3 -- bispecific antibody (cevostamab); BCMA -- antibody-drug conjugate (belantamab mafodotin)
Oct 23, 2026	NCT07609706	A Study of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With Multiple Myeloma and Moderate Hepatic Impairment	BCMA -- antibody-drug conjugate (Belantamab mafodotin); Proteasome -- proteasome inhibitor (Bortezomib); Glucocorticoid receptor -- corticosteroid agonist (Dexamethasone)

Source: ClinicalTrials.gov, synced daily. Aggregated by ClinTrialFinder.